LaRosaJCGrundySMWatersDD, et al.Treating to new targets I. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med2005; 352: 1425–1435.
2.
PiepoliMFHoesAWAgewallS, et al.ESC Scientific Document Group. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Eur Heart J2016; 37: 2315–2381.
3.
DykunIWiefhoffDTotzeckM, et al.Disconcordance between ESC prevention guidelines and observed lipid profiles in patients with known coronary artery disease. Int J Cardiol Heart Vasc2019; 22: 73–77.
4.
DanchinNAlmahmeedWAl-RasadiK, et al.for the ICLPS Investigators. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: the International ChoLesterol management Practice Study (ICLPS). Eur J Prev Cardiol2018; 25: 1087–1094.
5.
MunkhaugenJSverreEOtterstadJE, et al.Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients. Eur J Prev Cardiol2017; 24: 981–989.
6.
CannonCPBlazingMAGiuglianoRP, et al.for the IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med2015; 372: 2387–2397.
7.
SabatineMSGiuglianoRPKeechAC, et al.for the FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med2017; 376: 1713–1722.
8.
SchwartzGGStegPGSzarekM, et al.for the ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med2018; 379: 2097–2107.
9.
RidkerPMRevkinJAmarencoP, et al.for the SPIRE Cardiovascular Outcome Investigators. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med2017; 376: 1527–1539.
10.
HagiwaraNKawada-WatanabeEKoyanagiR, et al.Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. Eur Heart J2017; 38: 2264–2276.
11.
RobinsonJGFarnierMKrempfM, et al.for the ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med2015; 372: 1489–1499.
12.
SabatineMSGiuglianoRPWiviottSD, et al.Open-label study of long-term evaluation against LDL cholesterol clinical trial – OSLER. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med2015; 372: 1500–1509.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
